Literature DB >> 11925592

Transcription factor EGR-1 inhibits growth of hepatocellular carcinoma and esophageal carcinoma cell lines.

Miao-Wang Hao1, Ying-Rui Liang, Yan-Fang Liu, Li Liu, Ming-Yao Wu, Huan-Xing Yang.   

Abstract

AIM: The transcription factor EGR-1 (early growth response gene-1) plays an important role in cell growth, differentiation and development. It has identified that EGR-1 has significant transformation suppression activity in some neoplasms, such as fibrosarcoma, breast carcinoma. This experiment was designed to investigate the role of egr-1 in the cancerous process of hepatocellular carcinoma (HCC) and esophageal carcinoma (EC), and then to appraise the effects of EGR-1 on the growth of these tumor cells.
METHODS: Firstly, the transcription and expression of egr-1 in HCC and EC, paracancerous tissues and their normal counterpart parts were detected by in situ hybridization and immunohistochemistry, with normal human breast and mouse brain tissues as positive controls. Egr-1 gene was then transfected into HCC (HHCC, SMMC7721) and EC (ECa109) cell lines in which no egr-1 transcription and expression were present. The cell growth speed, FCM cell cycle, plate clone formation and tumorigenicity in nude mice were observed and the controls were the cell lines transfected with vector only.
RESULTS: Little or no egr-1 transcription and expression were detected in HCC, EC and normal liver tissues. The expression of egr-1 were found higher in hepatocellular paracancerous tissue (transcription level P=0.000; expression level P=0.143, probably because fewer in number of cases) and dysplastic tissue of esophageal cancer (transcription level P=0.000; expression level P=0.001). The growth rate of egr-1-transfected HHCC (HCC cell line) cells and ECa109 (EC cell line) cells was much slower than that of the controls. The proportion of S phase cell, clone formation and tumorigenicity were significantly lower than these of the controls' (decreased 45.5% in HHCC cells and 34.1% in ECa109 cells; 46.6% and 41.8%; 80.4% and 72.6% respectively). There were no obvious differences between SMMC7721 (HCC) egr-1-transfected cells and the controls with regard to the above items.
CONCLUSION: The decreased expression of egr-1 might play a role in the dysregulation of normal growth in the cancerous process of HCC and EC. Egr-1 gene of transfected HHCC and ECa109 cells showed obvious suppression of the cell growth and malignant phenotypes, but no suppression in SMMC7721 (HCC cell line) cells.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11925592      PMCID: PMC4658351          DOI: 10.3748/wjg.v8.i2.203

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  42 in total

1.  Preparation and purification of F(ab')(2) fragment from anti hepatoma mouse IgG(1) mAb.

Authors:  Cheng-Gang Liu; Mei-Cai Zhu; Zhi-Nan Chen
Journal:  World J Gastroenterol       Date:  1999-12       Impact factor: 5.742

2.  Expression of IGF- II, p53, p21 and HBxAg in precancerous events of hepatocarcinogenesis induced by AFB1 and/or HBV in tree shrews.

Authors:  Liu-Liang Qin; Jian-Jia Su; Yuan Li; Chun Yang; Ke-Chen Ban; Rue-Qi Yian
Journal:  World J Gastroenterol       Date:  2000-02       Impact factor: 5.742

3.  Molecular biology of Barrett's esophagus and esophageal cancer:role of p53.

Authors:  Alan G Casson
Journal:  World J Gastroenterol       Date:  1998-08       Impact factor: 5.742

4.  Sequencing of p53 mutation in established human hepatocellular carcinoma cell line of HHC4 and HHC15 in nude mice.

Authors:  Shan-Min Yang; Hong Zhou; Rui-Chuan Chen; Yu-Fang Wang; Fu Chen; Chang-Gong Zhang; Yun Zhen; Jiang-Hua Yan; Jin-Hua Su
Journal:  World J Gastroenterol       Date:  1998-12       Impact factor: 5.742

5.  Reduction of tumorigenicity of SMMC-7721 hepatoma cells by vascular endothelial growth factor antisense gene therapy.

Authors:  Y C Tang; Y Li; G X Qian
Journal:  World J Gastroenterol       Date:  2001-02       Impact factor: 5.742

6.  The transcription factor EGR-1 suppresses transformation of human fibrosarcoma HT1080 cells by coordinated induction of transforming growth factor-beta1, fibronectin, and plasminogen activator inhibitor-1.

Authors:  C Liu; J Yao; I de Belle; R P Huang; E Adamson; D Mercola
Journal:  J Biol Chem       Date:  1999-02-12       Impact factor: 5.157

7.  Role of EGR1 in regulation of stimulus-dependent CD44 transcription in B lymphocytes.

Authors:  J S Maltzman; J A Carman; J G Monroe
Journal:  Mol Cell Biol       Date:  1996-05       Impact factor: 4.272

8.  A novel repression module, an extensive activation domain, and a bipartite nuclear localization signal defined in the immediate-early transcription factor Egr-1.

Authors:  A L Gashler; S Swaminathan; V P Sukhatme
Journal:  Mol Cell Biol       Date:  1993-08       Impact factor: 4.272

9.  Suppression of v-sis-dependent transformation by the transcription factor, Egr-1.

Authors:  R P Huang; T Darland; D Okamura; D Mercola; E D Adamson
Journal:  Oncogene       Date:  1994-05       Impact factor: 9.867

10.  Analysis of N-ras gene mutation and p53 gene expression in human hepatocellular carcinomas.

Authors:  Dan Luo; Qi-Fu Liu; C Gove; NV Naomov; Jian-Jia Su; R Williams
Journal:  World J Gastroenterol       Date:  1998-04       Impact factor: 5.742

View more
  20 in total

1.  Identification of differentially expressed proteins between human esophageal immortalized and carcinomatous cell lines by two-dimensional electrophoresis and MALDI-TOF-mass spectrometry.

Authors:  Xing-Dong Xiong; Li-Yan Xu; Zhong-Ying Shen; Wei-Jia Cai; Jian-Min Luo; Ya-Li Han; En-Min Li
Journal:  World J Gastroenterol       Date:  2002-10       Impact factor: 5.742

2.  Separation and identification of differentially expressed nuclear matrix proteins between human esophageal immortalized and carcinomatous cell lines.

Authors:  Xing-Dong Xiong; En-Min Li; Li-Yan Xu; Hai-Bin Chen; Ling Chen; Wei-Jia Cai; Ya-Li Han; Zhong-Ying Shen; Yi Zeng
Journal:  World J Gastroenterol       Date:  2003-10       Impact factor: 5.742

3.  Study on immune function of dendritic cells in patients with esophageal carcinoma.

Authors:  Shen-Ren Chen; Yi-Ping Luo; Jin-Kun Zhang; Wei Yang; Zhi-Chao Zhen; Lin-Xin Chen; Wei Zhang
Journal:  World J Gastroenterol       Date:  2004-04-01       Impact factor: 5.742

4.  Tumor suppression by the EGR1, DMP1, ARF, p53, and PTEN Network.

Authors:  Kazushi Inoue; Elizabeth A Fry
Journal:  Cancer Invest       Date:  2018-11-05       Impact factor: 2.176

5.  Inhibitory effect of all-trans retinoic acid on human hepatocellular carcinoma cell proliferation.

Authors:  Yun-Feng Piao; Yang Shi; Pu-Jun Gao
Journal:  World J Gastroenterol       Date:  2003-09       Impact factor: 5.742

6.  Expression of e-cadherin and beta-catenin in human esophageal squamous cell carcinoma: relationships with prognosis.

Authors:  Xi-Jiang Zhao; Hui Li; Hua Chen; Yan-Xue Liu; Li-Hua Zhang; Su-Xiang Liu; Qing-Lai Feng
Journal:  World J Gastroenterol       Date:  2003-02       Impact factor: 5.742

7.  Large-scale analysis of network bistability for human cancers.

Authors:  Tetsuya Shiraishi; Shinako Matsuyama; Hiroaki Kitano
Journal:  PLoS Comput Biol       Date:  2010-07-08       Impact factor: 4.475

8.  Evidence of EGR1 as a differentially expressed gene among proliferative skin diseases.

Authors:  Min Fang; Sue Ann Wee; Karyn Ronski; Hongran Fan; Shiying Tao; Qun Lin
Journal:  Genomic Med       Date:  2007-07-25

9.  Expression of Egr-1, c-fos and cyclin D1 in esophageal cancer and its precursors: An immunohistochemical and in situ hybridization study.

Authors:  Ming-Yao Wu; Chu-Xiang Zhuang; Huan-Xing Yang; Ying-Rui Liang
Journal:  World J Gastroenterol       Date:  2004-02-15       Impact factor: 5.742

10.  Production of a human single-chain variable fragment antibody against esophageal carcinoma.

Authors:  Ming-Yan Xu; Xiao-Hu Xu; Geng-Zhen Chen; Xiao-Ling Deng; Jonathan Li; Xiao-Jun Yu; Mei-Zhen Chen
Journal:  World J Gastroenterol       Date:  2004-09-15       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.